Permethrin foam

Drug Profile

Permethrin foam

Alternative Names: PerFoamFive; PerFoamOne; Permethrin foam - Foamix

Latest Information Update: 27 May 2015

Price : $50

At a glance

  • Originator Foamix
  • Class Antiparasitics; Pyrethrins; Small molecules
  • Mechanism of Action Sodium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Pediculosis; Scabies

Most Recent Events

  • 02 May 2013 Clinical development is ongoing in Israel
  • 22 Sep 2010 Taro Pharmaceutical Industries has been acquired by Sun Pharmaceutical Industries
  • 07 Sep 2009 Clinical trials in Pediculosis in Israel (Topical, 5% foam)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top